Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKDEWH)

Drug Name
AcDif-Glu-Cha-Cys Drug Info
Synonyms
CHEMBL62433; AcDif-Glu-Cha-Cys; AC1LAAI7; Ac-Dif-Glu-Cha-Cys-OH; BDBM50096401; Ac-3,3-Diphenyl-L-Ala-L-Glu-3-cyclohexyl-L-Ala-L-Cys-OH; AcDif(3,3-diphenylalanine)-Glu-Cha(beta-cyclohexylalanine)-Cys; (4S)-4-[[(2S)-2-acetamido-3,3-diphenylpropanoyl]amino]-5-[[(2S)-3-cyclohexyl-1-[[(2R)-1-hydroxy-1-oxo-3-sulfanylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
484562
TTD Drug ID
DMKDEWH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Hepatitis C virus NS3 helicase (HCV NS3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GS-9451 DMF910Q Chronic HCV-1 infection 1E51.1 Phase 2 [2]
GS-9857 DMYU6P5 Hepatitis C virus infection 1E51.1 Phase 2 [3]
BILN-2061 DM2J36F Hepatitis virus infection 1E50-1E51 Phase 2 [4]
VBY-376 DMU263R Hepatitis C virus infection 1E51.1 Phase 1 [5]
ACH-2684 DMW6X0O Hepatitis C virus infection 1E51.1 Phase 1 [6]
BMS-605339 DMY7ZRA Hepatitis C virus infection 1E51.1 Terminated [7]
GNF-PF-3464 DMWAKHD Discovery agent N.A. Investigative [8]
AcAsp-D-Gla-Leu-Ile-Cha-Cys DMT74F5 Discovery agent N.A. Investigative [9]
Cbz-Ile-Leu-L-(difluoro)aminobutyric acid DMI53WR Discovery agent N.A. Investigative [9]
AcGlu-Dif-Ile-Cha-Cys DMK6HGI Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis C virus NS3 helicase (HCV NS3) TTWXB3E POLG_HCV1 Inhibitor [1]

References

1 Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.
2 Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients. Antimicrob Agents Chemother. 2012 October; 56(10): 5289-5295.
3 Clinical pipeline report, company report or official report of Gilead.
4 Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5.
5 Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 August; 2(8): 1752-1765.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem.2014 Mar 13;57(5):1708-29.
8 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
9 Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.